FT. LAUDERDALE, Fla., Sept. 27 /PRNewswire/ -- MitralSolutions, Inc., an early stage cardiovascular medical device company, today has announced Series B financing of $7 million to finance the development of innovative surgical and percutaneous medical devices for the treatment of valvular heart disease and congestive heart failure.
The Series B round was raised through a consortium of investors, led by Cardinal Partners, Princeton, NJ. Lisa Skeete Tatum, General Partner at Cardinal, will join the board.
MitralSolutions, Inc. technologies were invented and founded by clinicians and engineers experienced in the art of cardiac valve repair. The company will capitalize on the long-term experience of cardiac surgeons to develop cardiac valve repair technologies, both surgical and percutaneous, which put proven surgical techniques for cardiac valve repair in the hands of interventional cardiologists. “The development of cardiac valve repair devices that can be customized to a patient’s anatomy, while at the same time minimize technical complexity for the clinician, will improve outcomes and allow earlier treatment of patients with cardiac valve disease,” says MitralSolutions, Inc. President and Chief Executive Officer James L. Greene. “We see significant value in collaborating with the experts in cardiac valve repair and validating our core technologies in a surgical setting as the preferred process in developing reliable and effective percutaneous valve repair.”
With this round of funding, MitralSolutions, Inc. will be focused on the engineering and trials of its core technologies, as well as its initial product portfolio. An experienced team of clinicians, engineers, and management will lead this Ft. Lauderdale-based company.
About MitralSolutions, Inc.
Founded in February 2004 and headquartered in Ft. Lauderdale, Florida, MitralSolutions is currently developing technologies that enable both cardiovascular surgeons and interventional cardiologists to customize their treatment of cardiac valve abnormalities, such as mitral regurgitation, based on the patient’s individual anatomy and physiologic performance. The Company will introduce innovative valve repair products that can be delivered surgically or percutaneously to treat cardiac valve disease. These technologies are aimed to reduce the mortality and length of hospital stay associated with typical cardiac valve surgery. For more information, visit http://www.mitralsolutions.com.
About Cardinal Partners
Cardinal Partners is an early stage healthcare venture capital firm. For more information, visit http://www.cardinalpartners.com.
Cardinal Partners
CONTACT: Lisa Skeete Tatum, General Partner of Cardinal Partners,+1-609-924-6452
